{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000464","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2022-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.275276+00:00","generated_at":"2026-06-24T11:17:58.411110+00:00","sec_items":["3.02"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Regen Biopharma issues 54.5M shares to retire $180,552 convertible note with Coventry","bullets":["Issued 54,514,492 common shares to Coventry Enterprises LLC to satisfy $180,552 of convertible indebtedness.","Principal and accrued interest on $1.5M promissory note now $0 as of July 19, 2022.","Shares issued under Section 4(a)(2) exemption; no underwriter or commission paid.","Significant dilution for existing shareholders; all outstanding convertible debt now retired."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000464","json":"https://secwatch.observer/filing/0001607062-22-000464.json","markdown":"https://secwatch.observer/filing/0001607062-22-000464.md","text":"https://secwatch.observer/filing/0001607062-22-000464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000464/0001607062-22-000464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000464/rgbp072022form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:17:58.411110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}